Bachtel Hannah Agard, Flores Hunter, Park Bridget, Kim Soo Jeong, Koh Chester J, Janzen Nicolette K
Division of Pediatric Urology, Texas Children's Hospital and Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
J Pediatr Urol. 2023 Dec;19(6):742.e1-742.e8. doi: 10.1016/j.jpurol.2023.05.008. Epub 2023 May 13.
OnabotulinumtoxinA is used as treatment for refractory idiopathic and neurogenic detrusor overactivity in children. Many patients perform intermittent self-catheterization and therefore have higher rates of asymptomatic bacteriuria, which may increase their risk of symptomatic urinary tract infection (UTI) following treatment. Multiple injections are often needed due to the short-term efficacy of onabotulinumtoxinA treatment, which may also increase the risk of UTI.
We aim to evaluate whether a sterile urinary tract is necessary to decrease the risk of postoperative UTI in pediatric patients treated with onabotulinumtoxinA.
A retrospective review of patients undergoing intradetrusor onabotulinumtoxinA injection from 2014 to 2021 was performed. Demographic data, clinical characteristics, antibiotic treatment and culture results were collected. A positive urine culture was defined as ≥ 10 CFU/ml of uropathogenic bacteria. Our primary outcome was symptomatic UTI within 14 days of the procedure.
103 patients underwent 158 treatments with onabotulinumtoxinA. The incidence of postoperative UTI was 3.2%. The incidence of symptomatic postoperative UTI in patients with asymptomatic bacteriuria compared to those with sterile urine was not significantly different (3.8% vs 0%, p = 0.57). Obtaining a preoperative urinalysis or urine culture did not affect the incidence of postoperative UTI (p = 0.54). The number needed to treat with antibiotics to prevent one postoperative UTI was 27. The incidence of postoperative UTI was highest in patients with low-risk bladders (p = 0.043). Prior history of multi-drug resistant UTI was a risk factor for postoperative UTI (p = 0.048).
For children undergoing onabotulinumtoxinA injection, there are no evidence-based recommendations regarding antibiotic prophylaxis and the need to screen for and treat asymptomatic bacteruria prior to treatment. Our study addresses this important clinical question, and shows no difference in the rate of postoperative UTI between patients with asymptomatic bacteriuria and those with sterile urine. Patients with a history of multi-drug resistant UTI are at increased risk of symptomatic postoperative UTI and may benefit from preoperative urine testing and treatment. Limitations of our retrospective study include its small sample size in the face of such a low incidence of our primary outcome.
The risk of UTI following onabotulinumtoxinA injection in children is low. The presence of sterile urine at the time of surgery does not significantly decrease the risk of postoperative UTI. Routine treatment of asymptomatic bacteriuria prior to surgery results in a large number of patients receiving unnecessary antibiotics. As a result, we recommend against preoperative urine testing for most asymptomatic patients.
A型肉毒毒素被用于治疗儿童难治性特发性和神经源性逼尿肌过度活动症。许多患者进行间歇性自我导尿,因此无症状菌尿的发生率较高,这可能会增加他们治疗后发生有症状尿路感染(UTI)的风险。由于A型肉毒毒素治疗的短期疗效,通常需要多次注射,这也可能增加UTI的风险。
我们旨在评估无菌尿路对于降低接受A型肉毒毒素治疗的儿科患者术后UTI风险是否必要。
对2014年至2021年接受膀胱内A型肉毒毒素注射的患者进行回顾性研究。收集人口统计学数据、临床特征、抗生素治疗及培养结果。尿培养阳性定义为每毫升尿液中尿致病菌≥10 CFU。我们的主要结局是术后14天内发生有症状的UTI。
103例患者接受了158次A型肉毒毒素治疗。术后UTI的发生率为3.2%。无症状菌尿患者与无菌尿患者术后有症状UTI的发生率无显著差异(3.8%对0%,p = 0.57)。术前进行尿液分析或尿培养并不影响术后UTI的发生率(p = 0.54)。预防一例术后UTI所需的抗生素治疗人数为27。低风险膀胱患者术后UTI的发生率最高(p = 0.043)。多重耐药UTI的既往史是术后UTI的一个危险因素(p = 0.048)。
对于接受A型肉毒毒素注射的儿童,关于抗生素预防以及治疗前筛查和治疗无症状菌尿的必要性,尚无循证医学推荐。我们的研究解决了这个重要的临床问题,结果显示无症状菌尿患者与无菌尿患者术后UTI的发生率无差异。有多重耐药UTI病史的患者术后发生有症状UTI的风险增加,可能从术前尿液检测和治疗中获益。我们回顾性研究的局限性包括面对如此低的主要结局发生率时样本量较小。
儿童注射A型肉毒毒素后发生UTI的风险较低。手术时有无无菌尿并不会显著降低术后UTI的风险。术前常规治疗无症状菌尿会导致大量患者接受不必要的抗生素治疗。因此,我们建议大多数无症状患者无需进行术前尿液检测。